$-0.16 EPS Expected for Omeros Corporation (OMER)

February 15, 2018 - By Stephen Andrade

 $ 0.16 EPS Expected for Omeros Corporation (OMER)
Investors sentiment increased to 2.86 in Q3 2017. Its up 1.59, from 1.27 in 2017Q2. It increased, as 10 investors sold Omeros Corporation shares while 11 reduced holdings. 22 funds opened positions while 38 raised stakes. 22.04 million shares or 15.32% more from 19.11 million shares in 2017Q2 were reported.
Zurcher Kantonalbank (Zurich Cantonalbank) has 1,666 shares. First Interstate State Bank holds 5,000 shares or 0.02% of its portfolio. Price T Rowe Associate Md holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 12,613 shares. Hanseatic Mngmt Svcs reported 0.26% stake. Ameritas Prtnrs Inc accumulated 0% or 3,655 shares. Morgan Stanley owns 93,762 shares. Eam Limited Liability stated it has 202,025 shares. Alliancebernstein Limited Partnership accumulated 61,500 shares or 0% of the stock. Amp Cap Invsts has invested 0% in Omeros Corporation (NASDAQ:OMER). Swiss National Bank & Trust invested 0% in Omeros Corporation (NASDAQ:OMER). Tiaa Cref Investment Lc reported 114,207 shares. Tower Research Cap Ltd Limited Liability Company (Trc) holds 0.01% in Omeros Corporation (NASDAQ:OMER) or 4,645 shares. Proshare Advisors Ltd Liability reported 0.01% of its portfolio in Omeros Corporation (NASDAQ:OMER). Citigroup invested in 0% or 40,576 shares. California State Teachers Retirement System invested 0% in Omeros Corporation (NASDAQ:OMER).

Since January 3, 2018, it had 0 buys, and 2 sales for $1.36 million activity. Kelbon Marcia S. had sold 62,528 shares worth $1.34M.

Analysts expect Omeros Corporation (NASDAQ:OMER) to report $-0.16 EPS on March, 15.They anticipate $0.04 EPS change or 20.00 % from last quarter’s $-0.2 EPS. After having $-0.07 EPS previously, Omeros Corporation’s analysts see 128.57 % EPS growth. The stock decreased 2.22% or $0.25 during the last trading session, reaching $11. About 1.89M shares traded or 150.05% up from the average. Omeros Corporation (NASDAQ:OMER) has risen 42.59% since February 15, 2017 and is uptrending. It has outperformed by 25.89% the S&P500.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 9 analysts covering Omeros (NASDAQ:OMER), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Omeros had 26 analyst reports since August 10, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, June 13 by Maxim Group. The rating was maintained by Wedbush with “Buy” on Tuesday, November 28. The stock of Omeros Corporation (NASDAQ:OMER) has “Buy” rating given on Wednesday, November 29 by H.C. Wainwright. On Tuesday, January 23 the stock rating was maintained by H.C. Wainwright with “Buy”. WBB Securities maintained it with “Buy” rating and $7500 target in Tuesday, June 13 report. The firm has “Buy” rating given on Thursday, January 4 by H.C. Wainwright. The rating was downgraded by Cowen & Co on Thursday, November 2 to “Market Perform”. The firm has “Buy” rating by Needham given on Wednesday, November 11. H.C. Wainwright maintained Omeros Corporation (NASDAQ:OMER) on Thursday, December 14 with “Buy” rating. Cowen & Co maintained Omeros Corporation (NASDAQ:OMER) on Tuesday, August 18 with “Outperform” rating.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $528.04 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

More news for Omeros Corporation (NASDAQ:OMER) were recently published by: Fool.com, which released: “Here’s Why Omeros Corporation Is Getting Beaten Down on Wednesday” on February 14, 2018. Seekingalpha.com‘s article titled: “Omeros Corporation: What The Positive EMA’s Opinion Regarding OMS-721 Orphan …” and published on January 23, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.